IL2 and acute coronary syndrome: Recently, a large phase II double-blinded placebo-controlled clinical trial investigating the impact of low-dose IL-2 on vascular inflammation post-MI (IVORY [Low-Dose Interleukin 2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes])80 concluded that a potentially important subanalysis is evaluation of whether IL-2–induced Bregs are associated with a reduction in vascular inflammation.